Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People living with both viruses remain at risk for hepatocellular carcinoma despite antiviral therapy.
People who switched showed improvement in markers of kidney and bone health but also rise in lipid levels.
Researchers have challenged findings from a Chinese study that concluded Baraclude is tied to a lower risk of liver cancer.
New research shows that treating these viruses can reduce liver cancer risk.
People treated with the antivirals Viread, Vemlidy or Baraclude are less likely to develop hepatocellular carcinoma.
South Korean researchers found no difference in the rates of liver cancer, liver transplant or death based on the treatment used.
The drug is still associated with a lower liver cancer rate than Baraclude.
A quick overview of our reporting on the 53rd International Liver Congress in Vienna
Tenofovir was associated with a lower risk of hepatocellular carcinoma, but this might be related to other factors as well.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
Researchers analyzed a cohort of South Koreans taking Viread (tenofovir disoproxil fumarate) or Baraclude (entecavir) for hepatitis B.
With a grant to follow their large study population through 2021, researchers hope to gain vital new insights about HIV infection.
The exception is those people with hepatitis B and liver cancer.
Treatment with Viread and Baraclude led to a decline in liver cancer in Europe but not in South Korea.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.